Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK)

被引：13

作者：

Cano, Celine ^{[1
]}

Golding, Bernard T. ^{[1
]}

Haggerty, Karen ^{[1
]}

Hardcastle, Ian R. ^{[1
]}

Peacock, Marcus ^{[2
]}

Griffin, Roger J. ^{[1
]}

机构：

[1] Univ Newcastle, No Inst Canc Res, Sch Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] KuDOS Pharmaceut Ltd, Cambridge CB4 0PE, England

来源：

ORGANIC & BIOMOLECULAR CHEMISTRY | 2010年 / 8卷 / 08期

基金：

英国工程与自然科学研究理事会;

关键词：

DIRECTED ORTHO-METALATION; HUMAN TUMOR-CELLS; STRAND BREAK; POTENT; WORTMANNIN; RADIOSENSITIZATION; IDENTIFICATION; DISCOVERY; RADIATION; LY294002;

D O I：

10.1039/b926245h

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Substitution at the 3-position of the dibenzothiophen-4-yl ring of 8-(dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one NU7441, a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, with propyl, allyl or methyl enabled the separation by chiral HPLC of atropisomers. This is a consequence of restricted rotation about the dibenzothiophene-chromenone bond. Biological evaluation against DNA-PK of the pairs of atropisomers showed a marked difference in potency, with only one enantiomer being biologically active.

引用

页码：1922 / 1928

页数：7

共 50 条

[21] DNA-Dependent Protein Kinase (DNA-PK)-Dependent Cisplatin-Induced Loss of Nucleolar Facilitator of Chromatin Transcription (FACT) and Regulation of Cisplatin Sensitivity by DNA-PK and FACT
Dejmek, Janna
Iglehart, J. Dirk
Lazaro, Jean-Bernard
MOLECULAR CANCER RESEARCH, 2009, 7 (04) : 581 - 591
[22] Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Collins, Victor J.
Ludwig, Katelyn R.
Nelson, Ariana E.
Rajan, Soumya Sundara
Yeung, Choh
Vulikh, Ksenia
Isanogle, Kristine A.
Mendoza, Arnulfo
Difilippantonio, Simone
Karim, Baktiar O.
Caplen, Natasha J.
Heske, Christine M.
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (08) : 1109 - 1123
[23] Activation of DNA-dependent protein kinase (DNA-PK) may play a role in apoptosis of human neuroblastoma cells
Chakravarthy, BR
Walker, T
Rasquinha, I
Hill, IE
MacManus, JP
JOURNAL OF NEUROCHEMISTRY, 1999, 72 : S51 - S51
[24] DNA-dependent protein kinase (DNA-PK) phosphorylates and activates TonEBP/NFAT5 in response to hypertonicity
Lee, SD
Colla, E
Park, WK
Chen, DJ
Kwon, HM
FASEB JOURNAL, 2003, 17 (04): : A482 - A482
[25] DEVELOPMENT OF DNA-DEPENDENT PROTEIN-KINASE (DNA-PK) ASSAY SYSTEM USING HUMAN AUTOANTIBODIES AGAINST THE 350-KDA CATALYTIC SUBUNIT OF DNA-PK
SUWA, A
MIMORI, T
WATANABE, F
TERAOKA, H
HIRAKATA, M
INADA, S
HARDIN, JA
ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 1001 - 1001
[26] DNA-dependent protein kinase (DNA-PK) regulates V(D)J recombination by RAG2 phosphorylation
Kim, DR
Choi, Y
Son, YM
Hah, YS
FEBS JOURNAL, 2005, 272 : 290 - 291
[27] Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy
Boucher, D.
Hillier, S.
Newsome, D.
Wang, Y.
Takemoto, D.
Gu, Y.
Markland, W.
Hoover, R.
Arimoto, R.
Maxwell, J.
Fields, S. Z.
Charifson, P.
Penney, M. S.
Tanner, K.
ANNALS OF ONCOLOGY, 2016, 27
[28] The DNA-activated protein kinase - DNA-PK
Anderson, CW
Carter, TH
MOLECULAR ANALYSIS OF DNA REARRANGEMENTS IN THE IMMUNE SYSTEM, 1996, 217 : 91 - 111
[29] DNA ligase I activation during repair of alkylation damaged DNA is via DNA-dependent protein kinase (DNA-PK) mediated phosphorylation
Bhat, KR
Benton, BJ
Ray, R
FASEB JOURNAL, 1999, 13 (07): : A1453 - A1453
[30] A novel, selective inhibitor of DNA-dependent protein kinase (DNA-PK) potentiates the effects of DNA-damaging therapies in hepatocellular carcinoma
Willoughby, Catherine E.
Thomas, Huw D.
Rennison, Tommy
Cano, Celine
Reeves, Helen L.
Wedge, Stephen R.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →